Wyeth's Sales Tactics Not Anti-Competitive: Court

Law360, New York (May 11, 2007, 12:00 AM EDT) -- A group of pharmaceutical wholesalers has lost an appeal brought against Wyeth-Ayerst Laboratories over claims the drug maker hiked up the price of its hormone medication while keeping its competitor out of the lucrative market.

The U.S. Court of Appeals for the Sixth Circuit on Thursday affirmed a lower court’s granting of summary judgment to Wyeth, ruling the company had not violated federal antitrust laws despite the aggressive tactics it used to boost sales of Premarin at the expense of rival company Duramed.

The class of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.